GlassScriptPhysician profile
William K Brubaker
NPI 1336114016
$4,099.35
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $682 · 2021: $886 · 2022: $950 · 2023: $524 · 2024: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,315.71 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $396.37 | 2019-2024 | Airsupra, Farxiga |
| Abbott Laboratories | $215.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $212.25 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $198.46 | 2019-2021 | |
| Novo Nordisk INC | $195.95 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $177.09 | 2021 | |
| Abbvie INC. | $173.87 | 2019-2023 | Vraylar |
| Pfizer INC. | $151.49 | 2019-2024 | |
| Genentech USA, INC. | $148.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $130.08 | 2019-2022 | |
| Amgen INC. | $75.85 | 2019-2024 | Evenity, Prolia, Repatha |
| Allergan, INC. | $68.62 | 2020-2021 | |
| Exact Sciences Corporation | $65.46 | 2023-2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $62.36 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $60.74 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $59.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.22 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.17 | 2022-2024 | |
| Amarin Pharma, INC. | $39.93 | 2019-2021 | |
| Seqirus USA INC | $28.92 | 2019-2024 | Fluad, Flucelvax |
| Mylan Specialty L.P. | $28.63 | 2023 | Yupelri |
| Alexion Pharmaceuticals, INC. | $26.55 | 2022 | |
| Medtronic Vascular, INC. | $26.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.25 | 2020 | |
| Shield Therapeutics INC | $16.26 | 2023 | Accrufer |
| Nevro Corp. | $15.79 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.20 | 2020 | |
| Medicure Pharma INC. | $14.59 | 2021 | |
| Phadia US INC. | $13.56 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Brubaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.